Correlation between Prognostic Factors and the Histopathological Response to Neoadjuvant Chemotherapy in Osteosarcoma: A Retrospective Study

Table 1

Patient demographics and characteristics.

Features		n	%
Gender	Men	40	62.5
	Women	24	37.5
Age	>20 years	16	25.0
	≤20 years	48	75.0
Length of complaint	>12 weeks	47	73.4
	≤12 weeks	17	26.6
Tumor site	Distal	42	65.6
	Proximal	22	34.4
Osteosarcoma type	Conventional	61	95.31
	Telangiectatic	1	1.56
	Small cell	2	3.13
Tumor size (Ø)	≥10 cm	50	78.1
	<10 cm	14	21.9
Pathological fracture	Present	6	9.4
	Not identified	58	90.6
Preneoadjuvant chemotherapy ALP serum level	Increased	29	45.3
	Normal	35	54.7
Preneoadjuvant chemotherapy LDH serum level	Increased	63	98.5
	Normal	1	1.5
Staging	III	19	29.7
	IIB	45	70.3
Metastasis	Present	19	29.7
	Not identified	45	70.3
Postneoadjuvant chemotherapy tumor size	Enlarged	51	79.8
	Shrunk	13	20.2
Postneoadjuvant chemotherapy ALP serum level	Increased	24	37.5
	Normal	40	62.5
Increase in postneoadjuvant chemotherapy ALP serum level	Increased	20	31.3
	Decreased	44	68.7
Postneoadjuvant chemotherapy LDH serum level	Increased	63	98.5
	Normal	1	1.5
Increase in postneoadjuvant chemotherapy LDH serum level	Increased	33	51.6
	Decreased	31	48.4
Neoadjuvant chemotherapy number of cycles	<2 cycles	5	7.8
	≥2 cycles	59	92.2
Interval of neoadjuvant therapy to surgery	>4 weeks	33	51.6
	≤4 weeks	31	48.4
Surgical procedure	Ablation	27	42.2
	Salvage	37	57.8
Huvos response	Poor	49	76.6
	Good	15	23.4